| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/29/2004 | WO2004009020A2 Pyrrolopyrimidine thionucleoside analogs as antivirals |
| 01/29/2004 | WO2004009017A2 Modulators of the glucocorticoid receptor and method |
| 01/29/2004 | WO2004009015A2 Combination therapy for the treatment of obesity |
| 01/29/2004 | WO2003101492A3 Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain |
| 01/29/2004 | WO2003072572A8 Beta3-adrenergic receptor agonists |
| 01/29/2004 | WO2003066035A3 Compounds for inhibiting insulin secretion and methods related thereto |
| 01/29/2004 | WO2003065980A3 Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin |
| 01/29/2004 | WO2003061566A3 Anti-cancer combination and use thereof |
| 01/29/2004 | WO2003053971A8 Pyridoquinoxaline antivirals |
| 01/29/2004 | WO2003053923A3 Pyrrolidine derivatives as prostaglandin modulators |
| 01/29/2004 | WO2003050241A3 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
| 01/29/2004 | WO2003048775A3 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases |
| 01/29/2004 | WO2003042172A3 C-5 modified indazolylpyrrolotriazines |
| 01/29/2004 | WO2003041650A3 Modulation of lir function to treat rheumatoid arthritis |
| 01/29/2004 | WO2003038113A3 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 |
| 01/29/2004 | WO2003018047A3 Hdl for the treatment of stroke and other ischemic conditions |
| 01/29/2004 | WO2003009803A3 Method of improving cognitive function |
| 01/29/2004 | WO2003008635A3 η-SECRETASE IN VITRO SCREENING ASSAY |
| 01/29/2004 | WO2003000180A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/29/2004 | WO2002099060A3 Dgks as modifiers of the p53 pathway and methods of use |
| 01/29/2004 | WO2002072794A3 Immunoglobulin superfamily proteins |
| 01/29/2004 | WO2002070737A3 Compositions and methods relating to osteoarthritis |
| 01/29/2004 | WO2002064014A9 Endomural therapy |
| 01/29/2004 | WO2002038106A3 Calcilytic compounds |
| 01/29/2004 | US20040019190 Thrombopoietin mimetics |
| 01/29/2004 | US20040019121 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease |
| 01/29/2004 | US20040019113 Phosphate transport inhibitors |
| 01/29/2004 | US20040019107 A carbobenzoxy alanyl taurine has potency for treating virus infection, fatigue, allergic reaction, physiological disorders, metabolic disorders, proliferative disorders, immune dysfunctions, drug abuse; use as bactericides |
| 01/29/2004 | US20040019102 Administering a thiuram disulfide and a heavy metal ion; activated transcription factor/adenosine cyclic phosphate response element binding protein (atf/creb) |
| 01/29/2004 | US20040019099 Treating inflammatory diseases, allergic conditions and central nervous system disorders |
| 01/29/2004 | US20040019094 N-imine guanidine compounds; treatment of obesity, anorexia, inflammation and mental disorders |
| 01/29/2004 | US20040019089 Multidrug resistant cell inhibitors; anticancer agents |
| 01/29/2004 | US20040019085 Ureido-substituted aniline compounds useful as serine protease inhibitors |
| 01/29/2004 | US20040019072 Dimer-selective RXR modulators and methods for their use |
| 01/29/2004 | US20040019063 Nitrogen compounds such as 4-(7-Hydroxy-1,3-dioxo-tetrahydro-pyrrolo(1,2-c)imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile, used for prophylaxis of muscular disorders; aging |
| 01/29/2004 | US20040019060 Drugs such as 9-(3,5-dimethyl-1-piperazinyl)propyl)carbazole, used for modulating endothelial cell proliferation |
| 01/29/2004 | US20040019055 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/29/2004 | US20040019054 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/29/2004 | US20040019037 E.g.,((5-(2,4-Diaminopyrimidin-6-yl)pentanoyl)-(N-methyl)amino )-3-(6-meth-oxypyridin-3-yl)-propanoic acid, inhibition of bone resorption, restenosis, angiogenesis inhibitors, antiarthritic, -tumor, -carcinogenic agents; antidiabetic |
| 01/29/2004 | US20040019036 Treating a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia; able to induce or to improve hematologic response and/or cytogenetic response and, eventually, survival, with a mild non-hematologic toxicity |
| 01/29/2004 | US20040019035 3-(5,6,7,8-Tetrahydro-(1,8)naphthyridin-2-yl)-ethoxy)-11H-di-b enzo(1,4)oxazepin-10-yl)-acetic acid; inhibiting bone resorption; vascular restenosis; osteoporosis; angiogenesis inhibitors; diabetic retinopathy; anticarcinogenic agents |
| 01/29/2004 | US20040019028 Administering to a patient with mild cognitive impairment, a specific glucocorticoid receptor antagonist such as mifepristone to improve performance on a paragraph recall test |
| 01/29/2004 | US20040019020 Phosphinyl phosphonate compounds treat hyperphosphatemia, chronic renal failure, disorders of phosphate metabolism, hyperparathyroidism, uremic bone disease, soft tissue calcification or osteoporosis |
| 01/29/2004 | US20040019016 Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor |
| 01/29/2004 | US20040019015 Administering an effective amount of a protein tyrosine kinase inhibitor (containing first and second module) to the patient to protect against or to treat hearing loss |
| 01/29/2004 | US20040019011 Treatment of conitions and disease |
| 01/29/2004 | US20040018996 Unit dosage forms for the treatment of herpes simplex |
| 01/29/2004 | US20040018991 Topical treatment for mastalgia |
| 01/29/2004 | US20040018987 Redox therapy for tumors |
| 01/29/2004 | US20040018980 Novel FIZZ proteins |
| 01/29/2004 | US20040018972 Autoimmune diseases; antiallergens; rheumatic diseases; antiinflammatory agents |
| 01/29/2004 | US20040018968 Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
| 01/29/2004 | US20040018618 Genetic engineering; hybrid proteins; gene expression; human gene therapy |
| 01/29/2004 | US20040018605 Anticancer agents; autoimmune diseases; central nervous system disorders; polymerase chain reactions |
| 01/29/2004 | US20040018542 Phosphodiesterase enzymes |
| 01/29/2004 | US20040018525 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
| 01/29/2004 | US20040018508 Surrogate antibodies and methods of preparation and use thereof |
| 01/29/2004 | US20040018259 Use of at least one extract of a plant of the genus lannea in a cosmetic or dermopharmaceutical composition |
| 01/29/2004 | US20040018253 Administering a drug for which major clearance mechanism in humans is CYP2D6 mediated oxidative biotransformation in combination with a CYP2D6 inhibitor |
| 01/29/2004 | US20040018251 Petasite extract is recovered from plant of the genus Petasites; effective in treating gastrointestinal diseases, asthmas, pollinosis, dysmenorrhea, eczemas, migraines, psoriasis and high blood pressure |
| 01/29/2004 | US20040018248 Composition containing statins and calcium for improved cardiovascular health |
| 01/29/2004 | US20040018245 Use of potassium for production of cardioplegic solution for prevention of stone heart development during acute cardiac ventricular fibrillation in connection with cardiopulmonary resuscitation |
| 01/29/2004 | US20040018242 Nanoparticulate nystatin formulations |
| 01/29/2004 | US20040018234 Four different dosage forms, two antibiotics inhibiting protein and non-protein synthesis, one comprising immediate release and sustained release, the other three has sustained release forms, twenty-four hour period; bacterial infections |
| 01/29/2004 | US20040018214 Treating a non-spasm caused pain with botulinum toxin |
| 01/29/2004 | US20040018213 Treating a non-spasm caused pain with botulinum toxin |
| 01/29/2004 | US20040018212 Treating a non-spasm caused pain with botulinum toxin |
| 01/29/2004 | US20040018194 Administering proteins that bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement |
| 01/29/2004 | US20040018192 Integrin expression inhibitors |
| 01/29/2004 | US20040018184 Administering mixtures of monocytes and drugs selected from taxanes, alkaloids, antibiotics or enzyme inhibitors, as anticarcinogenic agents |
| 01/29/2004 | US20040018169 Method for reducing oxalate |
| 01/29/2004 | DE19964268B4 Verfahren zum Screenen einer Verbindung, welche die Wechselwirkung zwischen IGF-1R und einem der Polypeptide IIP-1 bis IIP-10 hemmt A method for screening a compound which inhibits the interaction between IGF-1R and IIP-one of the polypeptides 1 to IIP-10 |
| 01/29/2004 | DE10229379A1 EG-VEGF Rezeptor Antagonisten EG-VEGF receptor antagonists |
| 01/29/2004 | CA2493384A1 Medicinal composition for treating arteriosclerosis |
| 01/29/2004 | CA2493341A1 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| 01/29/2004 | CA2492861A1 Process for preparing certain pyrrolotriazine compounds |
| 01/29/2004 | CA2492806A1 Targeted agents for nerve regeneration |
| 01/29/2004 | CA2492665A1 Azaindole kinase inhibitors |
| 01/29/2004 | CA2492523A1 Novel inhibitors of ubiquitin isopeptidases |
| 01/29/2004 | CA2492498A1 Flea and tick octopamine receptor nucleic acid molecules, proteins and uses thereof |
| 01/29/2004 | CA2492331A1 Use of convertase inhibitors in the treatment of fibrosis and scarring |
| 01/29/2004 | CA2492225A1 Combination therapy for the treatment of obesity |
| 01/29/2004 | CA2466288A1 Methods of treating conditions associated with an edg-1 receptor |
| 01/28/2004 | EP1384998A1 Eyestrain model, method of constructing the same, evaluation method with the use of the model and drugs screened by using the evaluation method |
| 01/28/2004 | EP1384488A2 Method and kit for imaging organs and tissues, using labelled antibodies |
| 01/28/2004 | EP1384478A1 Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose |
| 01/28/2004 | EP1383927A2 New polynucleotides and polypeptides of the erythropoietin gene |
| 01/28/2004 | EP1383919A1 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/28/2004 | EP1383912A1 Pd-1, a receptor for b7-4, and uses therefor |
| 01/28/2004 | EP1383895A2 Polynucleotides and polypeptides of the ifnalpha-5 gene |
| 01/28/2004 | EP1383892A2 Human extracellular matrix and cell adhesion polypeptides |
| 01/28/2004 | EP1383884A2 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
| 01/28/2004 | EP1383883A2 Asthma-associated snps around microsatellite marker d2s308 and identification of human prolyl-oligopeptidase-dpp10 |
| 01/28/2004 | EP1383800A1 RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
| 01/28/2004 | EP1383798A2 Transporters and ion channels |
| 01/28/2004 | EP1383789A2 Proteins associated with cell growth, differentiation, and death |
| 01/28/2004 | EP1383786A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| 01/28/2004 | EP1383782A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| 01/28/2004 | EP1383743A2 Dual inhibitors of pde 7 and pde 4 |
| 01/28/2004 | EP1383731A1 Biaryl compounds as serine protease inhibitors |